M7824 (MSB0011359C), a bifunctional fusion protein made up of a monoclonal antibody against PD-L1 and the extracellular domain of human TGF-β receptor II, suppressed the tumor growth and metastasis more efficiently than treatment with either anti-PD-L1 antibody or TGF-β trap monotherapy. This evidence concerns the gene TGFB1 and neoplasm.